Ultragenyx拟以2.1亿美元出售罕见儿科疾病优先审评券
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
Ultragenyx宣布达成最终协议，以2.1亿美元出售一张罕见儿科疾病优先审评券（PRV）。该PRV来自FDA批准其GSDIa基因疗法GENGLYCOS（pariglasgene brecaparvovec-opnr，即DTX401）。交易交割需满足惯例条件，包括HSR等待期届满。
可跟踪PRV出售交割进度及2.1亿美元非稀释资金对管线推进和盈利路径的支撑。
NOVATO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million. Ultragenyx received the PRV upon U.S. Food and Drug Administration (FDA) approval of GENGLYCOS™ (pariglasgene brecaparvovec-opnr), also known as DTX401, the first treatment designed to address the underlying cause of glycogen storage disease type Ia (GSDIa).
“Monetizing this PRV provides significant non-dilutive capital to advance our efforts to bring forward first-ever therapies for rare and ultra-rare diseases, and supports our path to profitability,” said Howard Horn, chief financial officer and executive vice president, corporate strategy. “GENGLYCOS itself benefited from capital generated from a previous PRV sale, demonstrating the important role the PRV program plays in helping companies develop transformative therapies for rare disease patients.”
The closing of the PRV transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott Rodino Antitrust Improvements Act.
Jefferies LLC is serving as exclusive financial advisor and Gibson, Dunn and Crutcher LLP is serving as legal counsel to Ultragenyx on this transaction.
补充资料（6 节）药物、疾病与研究背景 · 法律与声明 · 投资者与媒体联系
药物、疾病与研究背景
About the Rare Pediatric Disease Priority Review Voucher Program
This U.S. FDA program is intended to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Under this program, a sponsor who receives an approval for a drug or biologic for a "rare pediatric disease" may qualify for a PRV that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor receives the PRV upon approval of the rare pediatric disease product application, and it can be sold or transferred.
About Ultragenyx
Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
法律与声明
Forward-Looking Statements and Use of Digital Media
Except for the historical information contained herein, the matters set forth in this press release, including statements relating to Ultragenyx’s expectations regarding the consummation and timing of the PRV transaction, the amount and receipt of the cash consideration, and the anticipated use and benefits of the proceeds, including advancing Ultragenyx’s pipeline and supporting its path to profitability, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements involve substantial risks and uncertainties that could cause Ultragenyx’s future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, risks and uncertainties relating to the satisfaction of the closing conditions for the PRV transaction, including expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, the possibility that the transaction may be delayed or may not close, Ultragenyx’s ability to realize the anticipated benefits of the transaction and use the proceeds as anticipated, the sufficiency of existing cash, cash equivalents and short-term investments to fund operations, the uncertainties inherent in clinical drug development and the regulatory approval process, risks related to serious or undesirable side effects of Ultragenyx’s products and product candidates, manufacturing risks, market acceptance, uncertainty related to insurance coverage and reimbursement, and the availability or commercial potential of Ultragenyx’s products and product candidates. Ultragenyx undertakes no obligation to update or revise any forward-looking statements.
For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Ultragenyx in general, see Ultragenyx’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 5, 2026, and its subsequent periodic reports filed with the SEC.
In addition to its SEC filings, press releases and public conference calls, Ultragenyx uses its investor relations website and social media outlets to publish important information about the company, including information that may be deemed material to investors, and to comply with its disclosure obligations under Regulation FD. Financial and other information about Ultragenyx is routinely posted and is accessible on Ultragenyx’s Investor Relations website (https://ir.ultragenyx.com/) and LinkedIn website (https://www.linkedin.com/company/ultragenyx-pharmaceutical-inc-/).
投资者与媒体联系
来源：Ultragenyx Pharmaceutical｜奥特拉吉尼克斯 · ir.ultragenyx.com